Somos una empresa de origen mexicano, joven, dinámica e innovadora; ocupados y preocupados para encontrar soluciones para mejorar la calidad de vida y la salud de todos aquellos que se benefician con el uso apropiado de nuestros productos.
Somos una extensa red que agrupa a empresas e instituciones que investigan, fabrican y comercializan productos farmacéuticos y dermo-cosméticos que cumplen con los más altos estándares de calidad, apegados al cumplimiento de la normatividad nacional: las buenas prácticas de fabricación, de documentación y analíticas.
Siendo la principal farmacéutica mexicana cotizando en la Bolsa Mexicana de Valores, hemos creado nuestro Portal de Inversionistas en donde se pueden conocer los resultados y avances que se tienen cada periodo.
Nos encontramos en constante crecimiento llevando la presencia de Genomma Lab a distintas partes del mundo, como Brasil, Argentina, Colombia, Estados Unidos, Perú, Ecuador, Chile y a nueve países más.
La generación de productos en pro de la salud pública que mejoren la calidad de vida, constituye un elemento de vital interés para Genomma Lab Internacional, por tal motivo trabajamos para fortalecer nuestro portafolio con más de 250 productos anuales en desarrollo, tanto de medicamentos como de cuidado personal.
KVK is a leader in the development and manufacture of high-quality, FDA-approved medicines that address unmet patient needs. We take pride in our ability to advance medical care and offer low-cost alternatives in response to today’s healthcare challenges. All of our products are manufactured, packaged and distributed by KVK in the United States.
VISION:
“By 2020, KVK will apply its relentless drive to manufacture high-quality, affordable generics in every major dosage form,” states Anthony Tabasso, CEO and President of KVK Tech. “And, all of our products will be made in the USA, right here in Pennsylvania.”
KVK is committed to expansion through alliances across all phases of operations, which is evidenced by the current construction of a 250,000-square-foot sterile injectable plant in nearby Langhorne and the purchase of the 461,000-square-foot Lockheed-Martin complex in Newtown.
We continue to explore strategic opportunities to add to our expanding portfolio and are aggressively pursuing research and development prospects, including investment in new molecular entities.
And, we continue with developments in oral solids, such as extended or slow release tablets or capsules, all the while maintaining high manufacturing standards and exemplary customer service.
MISSION:
To continually build on our promise to deliver safe, effective and affordable FDA-approved pharmaceuticals to meet our customers’ needs and ensure that patients have access to high-quality medicines when they need it.
Our confidence in our ability to execute and play a key role in the pharmaceutical marketplace is underscored by the dedication of our employees and their commitment to excellence in science, manufacturing, quality control, regulatory compliance and customer satisfaction.
Founded in 1994, QPharma is the industry leader in cloud-based software and services for life sciences. The Commercial Services division provides solutions that include sample management and distribution, product launch management, online training, and HCP/KOL targeting and engagement. Services offered by the company’s Professional Services division include validation services, project management, auditing, and training. QPharma is a National Association of Boards of Pharmacy Verified Accredited Wholesale Distributor, and an approved American Medical Association Database Licensee. To learn more, visit www.qpharmacorp.com.